MCID: ECL001
MIFTS: 51

Eclampsia

Categories: Cardiovascular diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Eclampsia

MalaCards integrated aliases for Eclampsia:

Name: Eclampsia 12 52 29 54 43 15 71 32
Eclampsia in Puerperium 12 71
Eclampsia, Postpartum 12
Postpartum Eclampsia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13593
MeSH 43 D004461
NCIt 49 C87167
SNOMED-CT 67 15938005
ICD10 32 O15 O15.2 O15.9
UMLS 71 C0013537 C0156678

Summaries for Eclampsia

Disease Ontology : 12 A pre-eclampsia characterized by the presence of seizures.

MalaCards based summary : Eclampsia, also known as eclampsia in puerperium, is related to preeclampsia/eclampsia 1 and severe pre-eclampsia, and has symptoms including seizures An important gene associated with Eclampsia is STOX1 (Storkhead Box 1), and among its related pathways/superpathways are Signaling events mediated by VEGFR1 and VEGFR2 and Glypican 1 network. The drugs Magnesium oxide and Magnesium Sulfate have been mentioned in the context of this disorder. Affiliated tissues include placenta, endothelial and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Eclampsia is the onset of seizures (convulsions) in a woman with pre-eclampsia. Pre-eclampsia is a... more...

Related Diseases for Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 506, show less)
# Related Disease Score Top Affiliating Genes
1 preeclampsia/eclampsia 1 33.8 SERPINC1 PEE1
2 severe pre-eclampsia 33.3 VEGFA SERPINC1 PGF PAPPA LGALS13 HLA-G
3 mild pre-eclampsia 33.2 VEGFA PGF PAPPA OXT LGALS13 FLT1
4 hypertensive encephalopathy 31.2 VEGFA PGF
5 hellp syndrome 31.2 VEGFA THBD SERPINC1 PGF MTHFR LGALS13
6 peripartum cardiomyopathy 30.9 VEGFA PGF FLT1
7 patau syndrome 30.6 PGF PAPPA LGALS13
8 chorioamnionitis 30.5 VEGFA OXT FLT1
9 retinal vascular disease 30.4 VEGFA PGF MTHFR FLT1
10 exudative vitreoretinopathy 1 30.3 VEGFA PGF FLT1
11 oligohydramnios 30.2 PGF PAPPA OXT
12 pre-eclampsia 30.1 VEGFA THBD TAC3 STOX1 SERPINC1 PGF
13 placental insufficiency 30.1 VEGFA SERPINC1 PGF PAPPA FLT1
14 pregnancy loss, recurrent 1 30.1 MTHFR HLA-G
15 antiphospholipid syndrome 30.0 THBD SERPINC1 PGF MTHFR
16 ectopic pregnancy 30.0 VEGFA PGF PAPPA FLT1
17 microvascular complications of diabetes 5 29.9 VEGFA PGF FLT1
18 vascular disease 29.8 VEGFA THBD SERPINC1 MTHFR ENG
19 retinal vein occlusion 29.8 VEGFA SERPINC1 MTHFR
20 thrombophilia due to thrombin defect 29.8 THBD SERPINC1 MTHFR
21 thrombophilia due to activated protein c resistance 29.8 THBD SERPINC1 MTHFR
22 homocysteinemia 29.7 THBD SERPINC1 MTHFR
23 placenta accreta 29.6 PGF PAPPA OXT FLT1
24 placental abruption 29.4 THBD SERPINC1 PGF PAPPA MTHFR HLA-G
25 central retinal vein occlusion 29.4 VEGFA SERPINC1 MTHFR
26 protein s deficiency 29.4 THBD SERPINC1 MTHFR
27 protein c deficiency 29.4 THBD SERPINC1 MTHFR
28 placenta disease 29.3 VEGFA SERPINC1 PGF PAPPA OXT MTHFR
29 stroke, ischemic 29.2 THBD SERPINC1 MTHFR ENG
30 pulmonary embolism 29.1 THBD SERPINC1 MTHFR
31 peripheral vascular disease 29.0 VEGFA THBD SERPINC1 ENG
32 blood coagulation disease 29.0 VEGFA THBD SERPINC1 MTHFR
33 malaria 28.7 VEGFA THBD SERPINC1 MTHFR FLT1 ENG
34 hypertension, essential 28.6 VEGFA THBD SERPINC1 PGF PAPPA OXT
35 myocardial infarction 28.2 VEGFA THBD SERPINC1 PGF PAPPA MTHFR
36 preeclampsia/eclampsia 4 12.7
37 preeclampsia/eclampsia 5 12.7
38 preeclampsia/eclampsia 2 12.4
39 preeclampsia/eclampsia 3 12.4
40 gestational diabetes 11.6
41 chorea gravidarum 11.2
42 encephalopathy 10.7
43 yemenite deaf-blind hypopigmentation syndrome 10.6
44 disseminated intravascular coagulation 10.6
45 acute kidney failure 10.6
46 hydrops, lactic acidosis, and sideroblastic anemia 10.6
47 thrombocytopenia 10.5
48 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 10.5
49 hemifacial spasm 10.5 VEGFA MTHFR
50 pulmonary edema 10.5
51 seizure disorder 10.5
52 ocular motor apraxia 10.5
53 cortical blindness 10.5
54 visual epilepsy 10.5
55 lipodermatosclerosis 10.5 VEGFA FLT1
56 cancer-associated retinopathy 10.5 VEGFA PGF FLT1
57 epithelioid hemangioendothelioma 10.5 VEGFA PGF FLT1
58 glomeruloid hemangioma 10.5 VEGFA FLT1 ENG
59 kuhnt-junius degeneration 10.5 VEGFA PGF FLT1
60 neovascular glaucoma 10.5 VEGFA PGF FLT1
61 blood group, globoside system 10.5 VEGFA PGF FLT1
62 macular retinal edema 10.5 VEGFA PGF FLT1
63 endophthalmitis 10.5 VEGFA PGF FLT1
64 intussusception 10.5 VEGFA PGF FLT1
65 kidney disease 10.5
66 angiokeratoma circumscriptum 10.5 VEGFA FLT1
67 headache 10.4
68 diabetic macular edema 10.4 VEGFA PGF FLT1
69 retinal detachment 10.4
70 hydatidiform mole, recurrent, 1 10.4
71 gestational trophoblastic neoplasm 10.4
72 primary cutaneous b-cell lymphoma 10.4 VEGFA FLT1
73 cardiovascular organ benign neoplasm 10.4 VEGFA FLT1 ENG
74 vascular cancer 10.4 VEGFA FLT1 ENG
75 degeneration of macula and posterior pole 10.4 VEGFA PGF FLT1
76 arteriovenous malformations of the brain 10.4 VEGFA FLT1 ENG
77 severe nonproliferative diabetic retinopathy 10.4 VEGFA PGF
78 thrombophilia 10.4
79 brain edema 10.4
80 body mass index quantitative trait locus 1 10.4
81 chronic kidney disease 10.3
82 autoimmune disease 10.3
83 colorectal adenoma 10.3 VEGFA MTHFR EPHX1
84 systemic lupus erythematosus 10.3
85 neonatal anemia 10.3 PGF PAPPA FLT1 ENG
86 twin-to-twin transfusion syndrome 10.3 PGF PAPPA FLT1 ENG
87 nephrotic syndrome 10.3
88 glomerulonephritis 10.3
89 purpura 10.3
90 cerebrovascular disease 10.3
91 48,xyyy 10.3
92 hypothyroidism 10.3
93 hyperuricemia 10.3
94 acquired hemangioma 10.3 VEGFA OXT
95 juvenile nasopharyngeal angiofibroma 10.3 VEGFA ENG
96 pain agnosia 10.2
97 47,xyy 10.2
98 chromosomal triplication 10.2
99 thrombotic thrombocytopenic purpura 10.2
100 asphyxia neonatorum 10.2
101 cerebral palsy 10.2
102 lupus erythematosus 10.2
103 cytokine deficiency 10.2
104 hypoxia 10.2
105 aspiration pneumonia 10.2
106 rickets 10.2
107 lipid metabolism disorder 10.2
108 late congenital syphilis 10.2 OXT ENG
109 peripheral artery disease 10.2 VEGFA THBD ENG
110 acute cystitis 10.2
111 choriocarcinoma 10.2
112 hemolytic anemia 10.2
113 periodontitis 10.2
114 hypoglycemia 10.2
115 atrial standstill 1 10.2
116 hair whorl 10.2
117 down syndrome 10.2
118 enterocolitis 10.2
119 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
120 hemolytic-uremic syndrome 10.2
121 status epilepticus 10.2
122 acute pancreatitis 10.2
123 congestive heart failure 10.2
124 diabetes mellitus 10.2
125 respiratory distress syndrome in premature infants 10.1
126 deficiency anemia 10.1
127 pyelonephritis 10.1
128 newborn respiratory distress syndrome 10.1
129 ischemia 10.1
130 infertility 10.1
131 fatty liver disease 10.1
132 triploidy 10.1
133 migraine with or without aura 1 10.1
134 microphthalmia, syndromic 10 10.1
135 cardiac arrest 10.1
136 thrombosis 10.1
137 placenta praevia 10.1
138 respiratory failure 10.1
139 heart disease 10.1
140 anuria 10.1
141 intracranial hypertension 10.1
142 bronchopulmonary dysplasia 10.1
143 diabetes mellitus, noninsulin-dependent 10.0
144 pulmonary hypertension 10.0
145 intrahepatic cholestasis of pregnancy 10.0
146 renal hypertension 10.0
147 hemiplegia 10.0
148 chlamydia 10.0
149 hypertensive retinopathy 10.0
150 polycystic ovary syndrome 10.0
151 bell's palsy 10.0
152 cholestasis 10.0
153 pancreatitis 10.0
154 hyperthyroidism 10.0
155 vasculitis 10.0
156 partial hydatidiform mole 10.0
157 thrombotic microangiopathy 10.0
158 spinal cord infarction 10.0 SERPINC1 MTHFR
159 persistent fetal circulation syndrome 10.0 VEGFA PGF OXT HLA-G
160 grange syndrome 10.0 THBD MTHFR
161 puerperal pulmonary embolism 10.0 SERPINC1 PGF
162 sudden sensorineural hearing loss 10.0 SERPINC1 MTHFR
163 acute mountain sickness 10.0 VEGFA FLT1
164 lateral sinus thrombosis 10.0 SERPINC1 MTHFR
165 hypertriglyceridemia, familial 10.0
166 triiodothyronine receptor auxiliary protein 10.0
167 proteasome-associated autoinflammatory syndrome 1 10.0
168 chlamydia pneumonia 10.0
169 cysticercosis 10.0
170 glucose intolerance 10.0
171 tetanus 10.0
172 adult respiratory distress syndrome 10.0
173 acute kidney tubular necrosis 10.0
174 focal segmental glomerulosclerosis 10.0
175 aspiration pneumonitis 10.0
176 sleep disorder 10.0
177 perinatal necrotizing enterocolitis 10.0
178 diabetes insipidus 10.0
179 postpartum psychosis 10.0
180 marantic endocarditis 10.0 SERPINC1 MTHFR
181 livedoid vasculitis 10.0 SERPINC1 MTHFR
182 intracranial sinus thrombosis 10.0 SERPINC1 MTHFR
183 branch retinal artery occlusion 9.9 VEGFA SERPINC1 MTHFR
184 atherosclerosis susceptibility 9.9
185 breast cancer 9.9
186 neurofibromatosis, type iv, of riccardi 9.9
187 immune deficiency disease 9.9
188 myasthenia gravis 9.9
189 body mass index quantitative trait locus 11 9.9
190 preterm premature rupture of the membranes 9.9
191 microvascular complications of diabetes 3 9.9
192 microvascular complications of diabetes 4 9.9
193 microvascular complications of diabetes 6 9.9
194 microvascular complications of diabetes 7 9.9
195 korean hemorrhagic fever 9.9
196 autism spectrum disorder 9.9
197 aphasia 9.9
198 chronic pyelonephritis 9.9
199 hydrocephalus 9.9
200 hantavirus hemorrhagic fever with renal syndrome 9.9
201 arteriovenous malformation 9.9
202 epilepsy 9.9
203 hyperinsulinism 9.9
204 endometriosis 9.9
205 temporal lobe epilepsy 9.9
206 thrombophlebitis 9.9
207 liver disease 9.9
208 hyperglycemia 9.9
209 inherited metabolic disorder 9.9
210 premenstrual tension 9.9
211 prothrombin-related thrombophilia 9.9
212 anoxia 9.9
213 inflammatory myopathy with abundant macrophages 9.9
214 intermittent claudication 9.9 VEGFA SERPINC1 PGF
215 blood protein disease 9.9 VEGFA SERPINC1 MTHFR
216 nonarteritic anterior ischemic optic neuropathy 9.9 VEGFA SERPINC1 MTHFR
217 moyamoya disease 1 9.9 VEGFA SERPINC1 MTHFR
218 mastoiditis 9.9 SERPINC1 MTHFR
219 hypercholesterolemia, familial, 1 9.8
220 ige responsiveness, atopic 9.8
221 pheochromocytoma 9.8
222 autism 9.8
223 diabetes mellitus, insulin-dependent 9.8
224 insulin-like growth factor i 9.8
225 sudden infant death syndrome 9.8
226 helicobacter pylori infection 9.8
227 body mass index quantitative trait locus 9 9.8
228 body mass index quantitative trait locus 8 9.8
229 coronary heart disease 1 9.8
230 body mass index quantitative trait locus 4 9.8
231 body mass index quantitative trait locus 10 9.8
232 body mass index quantitative trait locus 7 9.8
233 human immunodeficiency virus type 1 9.8
234 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
235 diabetes mellitus, ketosis-prone 9.8
236 body mass index quantitative trait locus 12 9.8
237 body mass index quantitative trait locus 14 9.8
238 antithrombin iii deficiency 9.8
239 alpha-1-antitrypsin deficiency 9.8
240 body mass index quantitative trait locus 18 9.8
241 hyperlipoproteinemia, type iii 9.8
242 body mass index quantitative trait locus 19 9.8
243 body mass index quantitative trait locus 20 9.8
244 sleep apnea 9.8
245 adrenal gland pheochromocytoma 9.8
246 apraxia 9.8
247 bone resorption disease 9.8
248 ovarian disease 9.8
249 diphtheria 9.8
250 hepatorenal syndrome 9.8
251 coronary artery anomaly 9.8
252 allergic hypersensitivity disease 9.8
253 locked-in syndrome 9.8
254 quadriplegia 9.8
255 uveitis 9.8
256 klebsiella pneumonia 9.8
257 papilledema 9.8
258 candidiasis 9.8
259 duodenal ulcer 9.8
260 focal epilepsy 9.8
261 shwartzman phenomenon 9.8
262 tricuspid valve insufficiency 9.8
263 rh isoimmunization 9.8
264 systemic scleroderma 9.8
265 liver cirrhosis 9.8
266 thyroid hyalinizing trabecular adenoma 9.8
267 connective tissue disease 9.8
268 end stage renal failure 9.8
269 polyhydramnios 9.8
270 scotoma 9.8
271 meningitis 9.8
272 postpartum depression 9.8
273 sickle cell disease 9.8
274 gestational diabetes insipidus 9.8
275 reversible cerebral vasoconstriction syndrome 9.8
276 cytomegalovirus infection 9.8
277 fainting 9.8
278 myoclonus 9.8
279 pik3ca-related overgrowth syndrome 9.8
280 glomerular disease 9.8
281 vein disease 9.8 VEGFA SERPINC1 PGF MTHFR
282 osteonecrosis 9.8 VEGFA SERPINC1 MTHFR ENG
283 meningococcemia 9.8 THBD SERPINC1
284 hepatic veno-occlusive disease 9.8 VEGFA THBD SERPINC1
285 legg-calve-perthes disease 9.7 THBD SERPINC1 MTHFR
286 inherited blood coagulation disease 9.7 THBD SERPINC1 MTHFR
287 retinal vascular occlusion 9.7 VEGFA SERPINC1 PGF MTHFR FLT1
288 retinal artery occlusion 9.7 VEGFA SERPINC1 PGF MTHFR FLT1
289 alzheimer disease 9.7
290 anisocoria 9.7
291 arteries, anomalies of 9.7
292 progressive familial heart block, type ia 9.7
293 coarctation of aorta 9.7
294 fibrosis of extraocular muscles, congenital, 1 9.7
295 attention deficit-hyperactivity disorder 9.7
296 renal cell carcinoma, nonpapillary 9.7
297 nail-patella syndrome 9.7
298 osteoporosis 9.7
299 parkinson disease, late-onset 9.7
300 polykaryocytosis inducer 9.7
301 neural tube defects 9.7
302 urate oxidase, pseudogene 9.7
303 volvulus of midgut 9.7
304 wilms tumor 1 9.7
305 anencephaly 9.7
306 carnitine-acylcarnitine translocase deficiency 9.7
307 gastroschisis 9.7
308 hemolytic uremic syndrome, atypical 1 9.7
309 homocystinuria due to deficiency of n -methylenetetrahydrofolate reductase activity 9.7
310 hydrops fetalis, nonimmune 9.7
311 hypogonadism, male 9.7
312 intracranial hypertension, idiopathic 9.7
313 familial mediterranean fever 9.7
314 myeloperoxidase deficiency 9.7
315 myxedema 9.7
316 periodontitis, chronic 9.7
317 thrombocytopenia-absent radius syndrome 9.7
318 intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked 9.7
319 wiskott-aldrich syndrome 9.7
320 fabry disease 9.7
321 46,xy sex reversal 1 9.7
322 ataxia and polyneuropathy, adult-onset 9.7
323 kearns-sayre syndrome 9.7
324 gallbladder disease 1 9.7
325 asthma 9.7
326 budd-chiari syndrome 9.7
327 wilms tumor 5 9.7
328 progressive familial heart block, type ib 9.7
329 meningioma, radiation-induced 9.7
330 huntington disease-like 2 9.7
331 meningioma, familial 9.7
332 resting heart rate, variation in 9.7
333 patent ductus arteriosus 1 9.7
334 anxiety 9.7
335 hypertensive nephropathy 9.7
336 aspirin resistance 9.7
337 hypertension, diastolic 9.7
338 bone mineral density quantitative trait locus 8 9.7
339 bone mineral density quantitative trait locus 15 9.7
340 aspergillosis 9.7
341 graft-versus-host disease 9.7
342 alacrima, achalasia, and mental retardation syndrome 9.7
343 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
344 helix syndrome 9.7
345 nephrotic syndrome, type 18 9.7
346 angina pectoris 9.7
347 west syndrome 9.7
348 dengue shock syndrome 9.7
349 familial partial lipodystrophy 9.7
350 exanthem 9.7
351 funisitis 9.7
352 vitamin b12 deficiency 9.7
353 metabolic acidosis 9.7
354 oculogyric crisis 9.7
355 simultanagnosia 9.7
356 gallbladder disease 9.7
357 myelomeningocele 9.7
358 non-alcoholic fatty liver disease 9.7
359 polycystic kidney disease 9.7
360 benign teratoma 9.7
361 sensorineural hearing loss 9.7
362 dermatomyositis 9.7
363 thalassemia 9.7
364 bacterial infectious disease 9.7
365 klippel-feil syndrome 9.7
366 esophageal atresia 9.7
367 malignant hypertension 9.7
368 henoch-schoenlein purpura 9.7
369 spinal meningioma 9.7
370 subdural empyema 9.7
371 hemopericardium 9.7
372 cardiac tamponade 9.7
373 hyperandrogenism 9.7
374 onchocerciasis 9.7
375 portal vein thrombosis 9.7
376 pericardial effusion 9.7
377 myopia 9.7
378 coronary artery vasospasm 9.7
379 esophagitis 9.7
380 optic neuritis 9.7
381 pica disease 9.7
382 goiter 9.7
383 dengue disease 9.7
384 neutropenia 9.7
385 graves' disease 9.7
386 spinal muscular atrophy 9.7
387 leukemia 9.7
388 dyscalculia 9.7
389 acute leukemia 9.7
390 thyroid crisis 9.7
391 guillain-barre syndrome 9.7
392 cardiovascular system disease 9.7
393 carotid stenosis 9.7
394 dementia 9.7
395 periventricular leukomalacia 9.7
396 crescentic glomerulonephritis 9.7
397 right bundle branch block 9.7
398 diarrhea 9.7
399 porphyria 9.7
400 color blindness 9.7
401 urethritis 9.7
402 hyperparathyroidism 9.7
403 hepatic infarction 9.7
404 facial paralysis 9.7
405 amenorrhea 9.7
406 splenic artery aneurysm 9.7
407 blackwater fever 9.7
408 toxic shock syndrome 9.7
409 bacteriuria 9.7
410 renal tubular acidosis 9.7
411 pyuria 9.7
412 46 xy gonadal dysgenesis 9.7
413 cholera 9.7
414 angioedema 9.7
415 alcohol use disorder 9.7
416 pneumothorax 9.7
417 heart septal defect 9.7
418 pericarditis 9.7
419 neuritis 9.7
420 atrial heart septal defect 9.7
421 hypogonadism 9.7
422 trichomoniasis 9.7
423 placental choriocarcinoma 9.7
424 hepatitis b 9.7
425 post-traumatic stress disorder 9.7
426 dental caries 9.7
427 gastroenteritis 9.7
428 cystic teratoma 9.7
429 bilirubin metabolic disorder 9.7
430 pyelitis 9.7
431 melancholia 9.7
432 membranoproliferative glomerulonephritis 9.7
433 kidney cortex necrosis 9.7
434 iga glomerulonephritis 9.7
435 gingivitis 9.7
436 lysosomal storage disease 9.7
437 myelitis 9.7
438 cellulitis 9.7
439 sagittal sinus thrombosis 9.7
440 pleural empyema 9.7
441 cranial nerve palsy 9.7
442 insulinoma 9.7
443 syphilis 9.7
444 coronary stenosis 9.7
445 secretory meningioma 9.7
446 lymphoplasmacyte-rich meningioma 9.7
447 holoprosencephaly 9.7
448 intracranial hypotension 9.7
449 pneumonia 9.7
450 mature teratoma 9.7
451 panic disorder 9.7
452 acute stress disorder 9.7
453 amphetamine abuse 9.7
454 compartment syndrome 9.7
455 axonal neuropathy 9.7
456 cerebral primitive neuroectodermal tumor 9.7
457 hypogonadotropism 9.7
458 muscular atrophy 9.7
459 myocarditis 9.7
460 peritonitis 9.7
461 duodenitis 9.7
462 subacute delirium 9.7
463 vascular dementia 9.7
464 rubella 9.7
465 neuromyelitis optica 9.7
466 amyloidosis 9.7
467 gas gangrene 9.7
468 acute myocardial infarction 9.7
469 diastolic heart failure 9.7
470 toxocariasis 9.7
471 toxoplasmosis 9.7
472 amaurosis fugax 9.7
473 central serous chorioretinopathy 9.7
474 congenital hydrocephalus 9.7
475 diploid-triploid mosaicism 9.7
476 eisenmenger syndrome 9.7
477 hemiplegic migraine 9.7
478 periodontal ehlers-danlos syndrome 9.7
479 precocious puberty 9.7
480 recurrent hydatidiform mole 9.7
481 abdominal wall defect 9.7
482 color vision deficiency 9.7
483 aneurysm 9.7
484 autonomic dysfunction 9.7
485 cerebral atrophy 9.7
486 cerebral hypoxia 9.7
487 febrile seizures 9.7
488 hypertonia 9.7
489 pituitary tumors 9.7
490 syncope 9.7
491 posttransplant acute limbic encephalitis 9.7
492 cerebrofacial arteriovenous metameric syndrome 9.7
493 gastric adenocarcinoma and proximal polyposis of the stomach 9.7
494 exercise-induced malignant hyperthermia 9.7
495 cocaine intoxication 9.7
496 rare cause of hypertension 9.7
497 mesial temporal lobe epilepsy with hippocampal sclerosis 9.7
498 acute motor axonal neuropathy 9.7
499 invasive mole 9.7
500 homocystinuria 9.7 THBD SERPINC1 MTHFR
501 central retinal artery occlusion 9.6 VEGFA SERPINC1
502 pulmonary artery disease 9.6 VEGFA THBD SERPINC1 MTHFR
503 varicose veins 9.6 VEGFA THBD SERPINC1 MTHFR
504 essential thrombocythemia 9.6 VEGFA THBD SERPINC1 MTHFR
505 behcet syndrome 9.6 THBD SERPINC1 MTHFR ERAP2
506 blood platelet disease 9.5 VEGFA THBD SERPINC1

Graphical network of the top 20 diseases related to Eclampsia:



Diseases related to Eclampsia

Symptoms & Phenotypes for Eclampsia

UMLS symptoms related to Eclampsia:


seizures

MGI Mouse Phenotypes related to Eclampsia:

45 (showing 3, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.9 CORIN ENG FLT1 INHBB NOSTRIN OXT
2 homeostasis/metabolism MP:0005376 9.8 CORIN ENG EPHX1 FLT1 HLA-G INHBB
3 integument MP:0010771 9.23 CORIN ENG INHBB MTHFR OXT PGF

Drugs & Therapeutics for Eclampsia

Drugs for Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 366, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium oxide Approved Phase 4 1309-48-4 14792
2
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Dinoprostone Approved Phase 4 363-24-6 5280360
5
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
6
leucovorin Approved Phase 4 58-05-9 6006 143
7
Remifentanil Approved Phase 4 132875-61-7 60815
8
Enoxaparin Approved Phase 4 9005-49-6 772
9
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
10
Dalteparin Approved Phase 4 9005-49-6
11
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
12
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
13
Clonidine Approved Phase 4 4205-90-7 2803
14
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
15
Captopril Approved Phase 4 62571-86-2 44093
16
Carbetocin Approved, Investigational Phase 4 37025-55-1 71715 16681432
17
Phenylephrine Approved Phase 4 59-42-7 6041
18
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
19
Acetaminophen Approved Phase 4 103-90-2 1983
20
Ibuprofen Approved Phase 4 15687-27-1 3672
21
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
22
Azithromycin Approved Phase 4 83905-01-5 55185 447043
23
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
24
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
25
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
26
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
27
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
28
Desogestrel Approved Phase 4 54024-22-5 40973
29
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
30
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
31
Metformin Approved Phase 4 657-24-9 14219 4091
32
Zinc Approved, Investigational Phase 4 7440-66-6 32051
33
Glyburide Approved Phase 4 10238-21-8 3488
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
35 Tocolytic Agents Phase 4
36 Anti-Arrhythmia Agents Phase 4
37 Anticonvulsants Phase 4
38 calcium channel blockers Phase 4
39 Antihypertensive Agents Phase 4
40 Antiemetics Phase 4
41 Autonomic Agents Phase 4
42 Adrenergic Agonists Phase 4
43 Adrenergic Agents Phase 4
44 Anesthetics, Local Phase 4
45 Sodium Channel Blockers Phase 4
46 Diuretics, Potassium Sparing Phase 4
47 Adrenergic alpha-2 Receptor Agonists Phase 4
48 calcium heparin Phase 4
49 Sympatholytics Phase 4
50 Angiotensin-Converting Enzyme Inhibitors Phase 4
51 Vitamin B Complex Phase 4
52 Vitamin B9 Phase 4
53 Folate Phase 4
54 Analgesics, Opioid Phase 4
55 Antibodies, Antiphospholipid Phase 4
56 Sodium Potassium Chloride Symporter Inhibitors Phase 4
57 Heparin, Low-Molecular-Weight Phase 4
58 Muscarinic Antagonists Phase 4
59 Butylscopolammonium Bromide Phase 4
60 Parasympatholytics Phase 4
61 Bromides Phase 4
62 Cholinergic Antagonists Phase 4
63 Adrenergic beta-Agonists Phase 4
64 Albuterol Phase 4
65 Anti-Asthmatic Agents Phase 4
66 Nasal Decongestants Phase 4
67 Respiratory System Agents Phase 4
68 Bronchodilator Agents Phase 4
69 Mydriatics Phase 4
70 Anti-Infective Agents Phase 4
71 Neuromuscular Agents Phase 4
72 Neuromuscular Blocking Agents Phase 4
73 Neuromuscular Nondepolarizing Agents Phase 4
74 Narcotics Phase 4
75 Cholinergic Agents Phase 4
76 Anti-Bacterial Agents Phase 4
77 Antibiotics, Antitubercular Phase 4
78 Cholinesterase Inhibitors Phase 4
79 Antitubercular Agents Phase 4
80 Hormones Phase 4
81 Hormone Antagonists Phase 4
82 Progestins Phase 4
83 Contraceptive Agents Phase 4
84 Contraceptives, Oral Phase 4
85
Ethylene Phase 4 74-85-1 6325
86 Analgesics Phase 4
87 Anti-Inflammatory Agents Phase 4
88 Fibrinolytic Agents Phase 4
89 Anti-Inflammatory Agents, Non-Steroidal Phase 4
90 Analgesics, Non-Narcotic Phase 4
91 Antipyretics Phase 4
92 Platelet Aggregation Inhibitors Phase 4
93 Cyclooxygenase Inhibitors Phase 4
94 Antirheumatic Agents Phase 4
95 Estrogens Phase 4
96 Hypoglycemic Agents Phase 4
97 Insulin, Globin Zinc Phase 4
98 insulin Phase 4
99 11-hydroxyprogesterone Phase 4
100 17 alpha-Hydroxyprogesterone Caproate Phase 4
101 Caproate Phase 4
102 Estrogen Receptor Antagonists Phase 4
103 Estrogen Antagonists Phase 4
104
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
105
Dexmedetomidine Approved, Vet_approved Phase 2, Phase 3 113775-47-6 68602 5311068
106
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
107
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
108
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
109
Atorvastatin Approved Phase 3 134523-00-5 60823
110
Morphine Approved, Investigational Phase 3 57-27-2 5288826
111
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7782-49-2
112
Salicylic acid Approved, Investigational, Vet_approved Phase 3 69-72-7 338
113
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
114
Benazepril Approved, Investigational Phase 3 86541-75-5 5362124
115
Theophylline Approved Phase 3 58-55-9 2153